Literature DB >> 16887932

Synergistic effects of peloruside A and laulimalide with taxoid site drugs, but not with each other, on tubulin assembly.

Ernest Hamel1, Billy W Day, John H Miller, M Katherine Jung, Peter T Northcote, Arun K Ghosh, Dennis P Curran, Mark Cushman, K C Nicolaou, Ian Paterson, Erik J Sorensen.   

Abstract

Previous studies on the drug content of pelleted tubulin polymers suggest that peloruside A binds in the laulimalide site, which is distinct from the taxoid site. In a tubulin assembly system containing microtubule-associated proteins and GTP, however, peloruside A was significantly less active than laulimalide, inducing assembly in a manner that was most similar to sarcodictyins A and B. Because peloruside A thus far seems to be the only compound that mimics the action of laulimalide, we examined combinations of microtubule-stabilizing agents for synergistic effects on tubulin assembly. We found that peloruside A and laulimalide showed no synergism but that both compounds could act synergistically with a number of taxoid site agents [paclitaxel, epothilones A/B, discodermolide, dictyostatin, eleutherobin, the steroid derivative 17beta-acetoxy-2-ethoxy-6-oxo-B-homo-estra-1,3,5(10)-trien-3-ol, and cyclostreptin]. None of the taxoid site compounds showed any synergism with each other. From an initial study with peloruside A and cyclostreptin, we conclude that the synergism phenomenon derives, at least in part, from an apparent lowering of the tubulin critical concentration with drug combinations compared with single drugs. The apparent binding of peloruside A in the laulimalide site led us to attempt construction of a pharmacophore model based on superposition of an energy-minimized structure of peloruside A on the crystal structure of laulimalide. Although the different sizes of the macrocycles limited our ability to superimpose the two molecules, atom correspondences that were observed were consistent with the difficulty so far experienced in creation of fully active analogs of laulimalide.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16887932     DOI: 10.1124/mol.106.027847

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  40 in total

1.  Total synthesis of laulimalide: synthesis of the northern and southern fragments.

Authors:  Barry M Trost; W Michael Seganish; Cheol K Chung; Dominique Amans
Journal:  Chemistry       Date:  2012-02-03       Impact factor: 5.236

Review 2.  Microtubule targeting agents: from biophysics to proteomics.

Authors:  D Calligaris; P Verdier-Pinard; F Devred; C Villard; D Braguer; Daniel Lafitte
Journal:  Cell Mol Life Sci       Date:  2010-01-28       Impact factor: 9.261

3.  Low-dose laulimalide represents a novel molecular probe for investigating microtubule organization.

Authors:  Melissa J Bennett; Gordon K Chan; J B Rattner; David C Schriemer
Journal:  Cell Cycle       Date:  2012-08-08       Impact factor: 4.534

4.  Peloruside- and laulimalide-resistant human ovarian carcinoma cells have βI-tubulin mutations and altered expression of βII- and βIII-tubulin isotypes.

Authors:  Arun Kanakkanthara; Anja Wilmes; Aurora O'Brate; Daniel Escuin; Ariane Chan; Ada Gjyrezi; Janet Crawford; Pisana Rawson; Bronwyn Kivell; Peter T Northcote; Ernest Hamel; Paraskevi Giannakakou; John H Miller
Journal:  Mol Cancer Ther       Date:  2011-06-08       Impact factor: 6.261

Review 5.  Microtubule-stabilizing agents as potential therapeutics for neurodegenerative disease.

Authors:  Kurt R Brunden; John Q Trojanowski; Amos B Smith; Virginia M-Y Lee; Carlo Ballatore
Journal:  Bioorg Med Chem       Date:  2013-12-30       Impact factor: 3.641

6.  Taccalonolide binding to tubulin imparts microtubule stability and potent in vivo activity.

Authors:  A L Risinger; J Li; M J Bennett; C C Rohena; J Peng; D C Schriemer; S L Mooberry
Journal:  Cancer Res       Date:  2013-09-18       Impact factor: 12.701

7.  Function-oriented synthesis: biological evaluation of laulimalide analogues derived from a last step cross metathesis diversification strategy.

Authors:  Susan L Mooberry; Michael K Hilinski; Erin A Clark; Paul A Wender
Journal:  Mol Pharm       Date:  2008-07-29       Impact factor: 4.939

8.  Peloruside B, a potent antitumor macrolide from the New Zealand marine sponge Mycale hentscheli: isolation, structure, total synthesis, and bioactivity.

Authors:  A Jonathan Singh; Chun-Xiao Xu; Xiaoming Xu; Lyndon M West; Anja Wilmes; Ariane Chan; Ernest Hamel; John H Miller; Peter T Northcote; Arun K Ghosh
Journal:  J Org Chem       Date:  2010-01-01       Impact factor: 4.354

Review 9.  Strategies for the synthesis of the novel antitumor agent peloruside A.

Authors:  David R Williams; Partha P Nag; Nicolas Zorn
Journal:  Curr Opin Drug Discov Devel       Date:  2008-03

Review 10.  Microtubule-stabilizing drugs from marine sponges: focus on peloruside A and zampanolide.

Authors:  John H Miller; A Jonathan Singh; Peter T Northcote
Journal:  Mar Drugs       Date:  2010-03-31       Impact factor: 5.118

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.